# Research Study: Medicinal Cannabis and Driving: A Survey of Australian Pharmacists > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medicinal-cannabis-driving-safety-survey-australian-pharmacists/ > **Published:** 2026-03-23T13:01:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:41:36-04:00 > **Clinical Summary:** Explore medicinal cannabis driving safety through a survey of Australian pharmacists, highlighting key knowledge gaps and patient counseling needs. --- ✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic Patient SafetyPharmacy PracticeImpairmentHealthcare EducationClinical Coordination Why This Matters Pharmacists serve as crucial safety gatekeepers in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), often providing the primary patient education about impairment risks and [driving safety](https://cedclinic.com/cannabis-cognitive-aging-older-adults-march-2026/). Understanding their knowledge gaps and comfort levels directly impacts patient safety outcomes and medication adherence in [clinical cannabis](https://cedclinic.com/entourage-effect-cannabis-clinical-breeding-benefits/) programs. Clinical Summary This Australian survey assessed pharmacists’ knowledge, attitudes, and practices regarding medicinal cannabis and [driving safety](https://cedclinic.com/cannabis-cognitive-aging-older-adults-march-2026/) counseling. The study likely revealed variable confidence levels among pharmacists in providing driving-related guidance to cannabis patients, reflecting broader educational needs in the pharmacy profession. Given that pharmacists are often the last healthcare touchpoint before patients use their medications, their preparedness to counsel on impairment and driving safety is clinically significant. Dr. Caplan’s Take “Pharmacists are often better positioned than physicians to provide nuanced, product-specific impairment counseling, but only if they have the clinical training to match that responsibility. This survey probably highlights what I see clinically — a profession ready to help but needing more robust cannabis-specific education.” Clinical Perspective 🧠 Clinicians prescribing cannabis should explicitly coordinate with dispensing pharmacists about patient-specific impairment risks and driving safety protocols. Patients benefit most when their entire care team — physician, pharmacist, and dispensary staff — provides consistent, evidence-based guidance about when it’s safe to drive after [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Research%20Study%3A%20Medicinal%20Cannabis%20and%20Driving%3A%20A%20Survey%20of%20Australian%20Pharmacis...%20%40drcaplan&url=https%3A//retailpharmacymagazine.com.au/research-study-medicinal-cannabis-and-driving-a-survey-of-australian-pharmacists/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//retailpharmacymagazine.com.au/research-study-medicinal-cannabis-and-driving-a-survey-of-australian-pharmacists/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Research%20Study%3A%20Medicinal%20Cannabis%20and%20Driving%3A%20A%20Survey%20of%20Australian%20Pharmacis...%20--%20via%20%40drcaplan.bsky.social%20https%3A//retailpharmacymagazine.com.au/research-study-medicinal-cannabis-and-driving-a-survey-of-australian-pharmacists/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://retailpharmacymagazine.com.au/research-study-medicinal-cannabis-and-driving-a-survey-of-australian-pharmacists/](https://retailpharmacymagazine.com.au/research-study-medicinal-cannabis-and-driving-a-survey-of-australian-pharmacists/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance of this cannabis-related news?](#What_is_the_clinical_relevance_of_this_cannabis-related_news) - [What key areas does this cannabis news cover?](#What_key_areas_does_this_cannabis_news_cover) - [Why is patient safety emphasized in cannabis healthcare?](#Why_is_patient_safety_emphasized_in_cannabis_healthcare) - [How does this relate to pharmacy practice?](#How_does_this_relate_to_pharmacy_practice) - [What should healthcare providers know about cannabis-related impairment?](#What_should_healthcare_providers_know_about_cannabis-related_impairment) - [Related](#Related) ## FAQ #### What is the clinical relevance of this cannabis-related news? This article has been rated as having high clinical relevance (#80) by CED Clinical. It contains strong evidence or policy relevance with direct clinical implications for healthcare practitioners. #### What key areas does this cannabis news cover? The article focuses on patient safety, pharmacy practice, impairment issues, and healthcare education. These are critical areas for healthcare providers working with [cannabis therapeutics](https://cedclinic.com/firearms-regulatory-guidance-cannabis/). #### Why is patient safety emphasized in cannabis healthcare? Patient safety is a primary concern when dealing with [cannabis therapeutics](https://cedclinic.com/firearms-regulatory-guidance-cannabis/) due to potential interactions, dosing considerations, and impairment effects. Healthcare providers must carefully monitor patients to prevent adverse outcomes. #### How does this relate to pharmacy practice? Pharmacists play a crucial role in cannabis therapeutics by providing guidance on proper dosing, drug interactions, and patient counseling. This news likely addresses important practice considerations for pharmacy professionals. #### What should healthcare providers know about cannabis-related impairment? Healthcare providers need to understand how cannabis can affect cognitive and motor functions in patients. This knowledge is essential for making informed recommendations about dosing, timing, and activities to avoid while using cannabis therapeutically. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Research Study: Medicinal Cannabis and Driving: A Survey of Australian Pharmacists”, “url”: “https://retailpharmacymagazine.com.au/research-study-medicinal-cannabis-and-driving-a-survey-of-australian-pharmacists/”, “datePublished”: “2026-03-23T13:03:46Z”, “about”: “research study medicinal cannabis driving survey”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Frequent cannabis users show no driving impairment 'the morning after' after smoking, study finds](https://cedclinic.com/frequent-cannabis-use-driving-safety-no-morning-after-impairment/) This study explores the effects of cannabis on driving impairment the day after use, providing insights relevant to patient counseling. [Read More](https://cedclinic.com/frequent-cannabis-use-driving-safety-no-morning-after-impairment/) [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Discover recent clinical findings on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and its impact on patient health outcomes and safety. [Explore Insights](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) [Rescheduling marijuana would open the doors for researchers to study THC and CBD.](https://cedclinic.com/rescheduling-marijuana-research-barriers-thc-cbd-studies/) Learn about how marijuana rescheduling could enhance research opportunities on THC and CBD effects. [Learn More](https://cedclinic.com/rescheduling-marijuana-research-barriers-thc-cbd-studies/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).